Lv51
838 积分 2022-07-21 加入
NSCLC: Five trials to watch
11天前
已关闭
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
12天前
已完结
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC – A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)
14天前
已完结
A Clinical Model to Estimate Recurrence Risk in Resected Stage I Non-Small Cell Lung Cancer
15天前
已完结
Microbiota and immune-related adverse events in cancer immunotherapy
1个月前
已完结
Combination of Radiotherapy and Immunotherapy in Advanced Non–Small Cell Lung Cancer
1个月前
已完结
Outcomes and Treatments of Patients With Non–Small Cell Lung Cancer Who Received Pembrolizumab
1个月前
已完结
CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-Analysis
1个月前
已关闭
A machine learning model integrating circulating Temra cell transcriptional profiles to predict immunotherapy efficacy
2个月前
已完结
皖公网安备34019202002308
